Enhanced Anti-angiogenic Effect of E7820 in Combination with Erlotinib in Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor-resistant Non-small-cell Lung Cancer Xenograft Models

Overview

Journal Cancer Sci

Specialty Oncology

Date 2014 May 21

PMID 24841832

Citations 14

Authors

Ken Ito

Taro Semba

Toshimitsu Uenaka

Toshiaki Wakabayashi

Makoto Asada

Yasuhiro Funahashi

Affiliations

Soon will be listed here.

Abstract

Most non-small-cell lung cancers (NSCLCs) harboring activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, they invariably develop resistance to these drugs. E7820 is an angiogenesis inhibitor that decreases integrin-α2 expression and is currently undergoing clinical trials. We investigated whether E7820 in combination with erlotinib, an EGFR-TKI, could overcome EGFR-TKI-resistance in the NSCLC cell lines A549 (KRAS; G12S), H1975 (EGFR; L858R/T790M), and H1650 (PTEN; loss, EGFR; exon 19 deletion), which are resistant to erlotinib. Immunohistochemical analysis was carried out in xenografted tumors to investigate anti-angiogenesis activity and endothelial cell apoptosis levels by endothelial cell marker CD31 and TUNEL staining, respectively. Treatment with E7820 (50 mg/kg) with erlotinib (60 mg/kg) showed a synergistic antitumor effect in three xenograft models. Immunohistochemical analysis indicated that combined treatment with E7820 and erlotinib significantly decreased microvessel density and increased apoptosis of tumor-associated endothelial cells compared with use of only one of the agents. This combination increased apoptosis in HUVECs through activation of both intrinsic and extrinsic apoptosis pathways in vitro. The combination of E7820 with erlotinib is an alternative strategy to overcome erlotinib resistance in NSCLC by enhancement of the anti-angiogenic activity of E7820.

Citing Articles

Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells.

Deng L, Jin K, Zhou X, Zhang Z, Ge L, Xiong X Precis Clin Med. 2022; 5(2):pbac007.

PMID: 35694719 PMC: 9113335. DOI: 10.1093/pcmedi/pbac007.

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.

Liu Y, Xiong Z, Sun X, Sun L, Zhang S, Ma J Transl Cancer Res. 2022; 8(5):2151-2163.

PMID: 35116965 PMC: 8798075. DOI: 10.21037/tcr.2019.09.35.

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells.

Nottingham E, Mazzio E, Surapaneni S, Kutlehria S, Mondal A, Badisa R J Pharm Anal. 2022; 11(6):799-807.

PMID: 35028186 PMC: 8740161. DOI: 10.1016/j.jpha.2021.06.002.

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design.

Kejik Z, Kaplanek R, Dytrych P, Masarik M, Vesela K, Abramenko N Pharmaceutics. 2021; 13(11).

PMID: 34834295 PMC: 8619417. DOI: 10.3390/pharmaceutics13111879.

The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression.

Hulskamp M, Kronenberg D, Stange R BMC Cancer. 2021; 21(1):571.

PMID: 34006252 PMC: 8132423. DOI: 10.1186/s12885-021-08301-w.

References

Gridelli C, Bareschino M, Schettino C, Rossi A, Maione P, Ciardiello F . Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007; 12(7):840-9. DOI: 10.1634/theoncologist.12-7-840. View

de La Motte Rouge T, Galluzzi L, Olaussen K, Zermati Y, Tasdemir E, Robert T . A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007; 67(13):6253-62. DOI: 10.1158/0008-5472.CAN-07-0538. View

Riely G, Marks J, Pao W . KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009; 6(2):201-5. DOI: 10.1513/pats.200809-107LC. View

Jin G, Kim M, Jeon H, Choi J, Kim D, Lee E . PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2009; 69(3):279-83. DOI: 10.1016/j.lungcan.2009.11.012. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Kim T, Murren J . Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs. 2002; 3(9):1385-95. View

Sos M, Koker M, Weir B, Heynck S, Rabinovsky R, Zander T . PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009; 69(8):3256-61. PMC: 2849653. DOI: 10.1158/0008-5472.CAN-08-4055. View

Sutter A, Hopfner M, Huether A, Maaser K, Scherubl H . Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer. 2005; 118(7):1814-22. DOI: 10.1002/ijc.21512. View

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C . Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012; 343(2):342-50. DOI: 10.1124/jpet.112.197756. View

10.

Besse B, Tsao L, Chao D, Fang Y, Soria J, Almokadem S . Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2012; 24(1):90-6. DOI: 10.1093/annonc/mds281. View

11.

Rogosin S, Sandler A . Beyond bevacizumab: antiangiogenic agents. Clin Lung Cancer. 2012; 13(5):326-33. DOI: 10.1016/j.cllc.2011.12.001. View

12.

Mita M, Kelly K, Mita A, Ricart A, Romero O, Tolcher A . Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011; 17(1):193-200. DOI: 10.1158/1078-0432.CCR-10-0010. View

13.

Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P . Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009; 15(10):3495-502. DOI: 10.1158/1078-0432.CCR-08-2407. View

14.

Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M . Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Sci. 2009; 100(8):1526-31. PMC: 11158850. DOI: 10.1111/j.1349-7006.2009.01197.x. View

15.

Dillon L, Miller T . Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014; 15(1):65-79. PMC: 4310752. DOI: 10.2174/1389450114666140106100909. View

16.

Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M . Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007; 18(8):1400-7. DOI: 10.1093/annonc/mdm140. View

17.

Huether A, Hopfner M, Sutter A, Schuppan D, Scherubl H . Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005; 43(4):661-9. DOI: 10.1016/j.jhep.2005.02.040. View

18.

Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V . Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2012; 24(1):109-16. DOI: 10.1093/annonc/mds284. View

19.

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G . Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer. 2012; 12(3):207-14. DOI: 10.1016/j.clbc.2012.03.008. View

20.

Kawahara E, Nakada N, Hikichi T, Kobayashi J, Nakanishi I . EGF and beta1 integrin convergently regulate migration of A431 carcinoma cell through MAP kinase activation. Exp Cell Res. 2001; 272(1):84-91. DOI: 10.1006/excr.2001.5399. View